The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase II randomized control trial of erlotinib in combination with celecoxib in patients with operable oral squamous cell carcinoma (OSCC): Erlo-Xib Study.
 
Sudhir Vasudevan Nair
No Relationships to Disclose
 
Amit Joshi
No Relationships to Disclose
 
Vijay Maruti Patil
No Relationships to Disclose
 
Vanita Noronha
Patents, Royalties, Other Intellectual Property - Research grant from Dr. Reddy's laboratory (Inst)
 
Nilesh Sable
No Relationships to Disclose
 
Abhishek Mahajan
No Relationships to Disclose
 
Bhasker Dharavath
No Relationships to Disclose
 
Nilesh Gardi
No Relationships to Disclose
 
Munita Bal
No Relationships to Disclose
 
Deepa Nair
No Relationships to Disclose
 
Tejpal Gupta
No Relationships to Disclose
 
Sarbani Laskar
No Relationships to Disclose
 
Jaiprakash Agarwal
No Relationships to Disclose
 
Pankaj Chaturvedi
No Relationships to Disclose
 
Amit Dutt
No Relationships to Disclose
 
Anil D'Cruz
No Relationships to Disclose
 
Sudeep Gupta
Research Funding - Amgen (Inst); Celltrion (Inst); Johnson & Johnson (Inst); Novartis (Inst); Oncostem Diagnostics (Inst); Roche (Inst); Sanofi (Inst)
 
Kumar Prabhash
No Relationships to Disclose